Literature DB >> 7494230

Five leading U.S. commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines.

D Hoffmann1, M V Djordjevic, J Fan, E Zang, T Glynn, G N Connolly.   

Abstract

BACKGROUND: Moist snuff is the only tobacco product in the United States with increasing sales (an increase of 38.4% between 1981 and 1993) and with increased consumption, primarily by male adolescents aged 12-18 years old and young adults aged 19 years old or older. It is known from previous studies that levels of nicotine and the proportion of unprotonated (free) nicotine, as well as the pH, which affects nicotine delivery, vary considerably among the leading snuff brands. Whether concentrations of major carcinogens, such as the nicotine-derived tobacco-specific N-nitrosamines (TSNAs), like N'-nitrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), also vary among these brands has not been determined previously.
PURPOSE: Our purpose was threefold: 1) to determine the concentrations of major carcinogenic nicotine-derived N-nitrosamines in each of the five most popular moist snuff brands; 2) to analyze the quantitative differences in the various snuff components (e.g., NNN) between two major brand categories: a category comprising the brands known to have high levels of unprotonated nicotine (Copenhagen, Skoal fine cut, and Kodiak) versus a category comprising the brands known to have low levels (Hawken and Skoal Bandits); and 3) to compare the differences in the concentrations of nicotine (previously determined), NNN, NNK, and total TSNAs between these two major brand categories.
METHODS: Three boxes of each of the five leading U.S. moist snuff brands were bought in July 1994 from retailers in six areas and transferred immediately to the analytical laboratory. After extraction, N-nitrosamino acids and TSNAs were determined on a gas chromatograph interfaced with a thermal energy analyzer (GC-TEA) and integrator. Each 5-g sample of ground, freeze-dried tobacco was extracted twice, and each extract was analyzed twice by GC-TEA. All P values reported are two sided.
RESULTS: Copenhagen, Skoal fine cut, and Kodiak as a group had statistically significant higher levels of nicotine (P = .0017), NNN (P < .0001), NNK (P = .0119), and total TSNAs (P < .0001) than the Hawken and Skoal Bandits group. Concentrations (means +/- SD) of nicotine, NNN, NNK, and total TSNAs comparing the two major brand categories are as follows: nicotine--11.6 +/- 1.01 mg/g versus 6.96 +/- 3.62 mg/g (P = .0017), NNN--7.74 +/- 1.70 micrograms/g versus 4.17 +/- 1.35 micrograms/g (P < .0001), NNK--1.23 +/- 0.68 micrograms/g versus 0.61 +/- 0.41 micrograms/g (P = .0119), and total TSNAs--14.3 +/- 3.82 micrograms/g versus 6.3 +/- 2.56 micrograms/g (P < .0001).
CONCLUSIONS: The three leading U.S. snuff brands (Copenhagen, Skoal fine cut, and Kodiak; making up 92% of the U.S. market) showed not only high levels of pH, nicotine, and unprotonated (free) nicotine, but also high concentrations of the strongly carcinogenic TSNAs in comparison with the fourth and fifth best selling moist snuff brands, Hawken and Skoal Bandits (3% of the U.S. market).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494230     DOI: 10.1093/jnci/87.24.1862

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  18 in total

1.  Smokeless tobacco cessation cluster randomized trial with rural high school males: intervention interaction with baseline smoking.

Authors:  Margaret M Walsh; Timothy J Langer; Niall Kavanagh; Chuck Mansell; William MacDougal; Catherine Kavanagh; Stuart A Gansky
Journal:  Nicotine Tob Res       Date:  2010-05-03       Impact factor: 4.244

2.  Levels of toxins in oral tobacco products in the UK.

Authors:  A McNeill; R Bedi; S Islam; M N Alkhatib; R West
Journal:  Tob Control       Date:  2006-02       Impact factor: 7.552

3.  Analysis of Tobacco-Specific Nitrosamines in the Common Smokeless Tobacco Afzal in Oman.

Authors:  Nawal Al-Mukhaini; Taher Ba-Omar; Elsadig A Eltayeb; Aisha A Al-Shehi
Journal:  Sultan Qaboos Univ Med J       Date:  2016-02-02

4.  Snus use, smoking and survival among prostate cancer patients.

Authors:  Kathryn M Wilson; Sarah C Markt; Fang Fang; Caroline Nordenvall; Jennifer R Rider; Weimin Ye; Hans-Olov Adami; Pär Stattin; Olof Nyrén; Lorelei A Mucci
Journal:  Int J Cancer       Date:  2016-12-15       Impact factor: 7.396

Review 5.  Pancreatic Cancer Screening.

Authors:  Koushik K Das; Dayna Early
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

6.  Characterisation of Nicotine and Cancer-Enhancing Anions in the Common Smokeless Tobacco Afzal in Oman.

Authors:  Nawal M Al-Mukhaini; Taher A Ba-Omar; Elsadig A Eltayeb; Aisha H Al-Shehi
Journal:  Sultan Qaboos Univ Med J       Date:  2015-11-23

Review 7.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 8.  Effect of smokeless tobacco (snus) on smoking and public health in Sweden.

Authors:  J Foulds; L Ramstrom; M Burke; K Fagerström
Journal:  Tob Control       Date:  2003-12       Impact factor: 7.552

9.  Chemical analysis of Alaskan Iq'mik smokeless tobacco.

Authors:  Bryan A Hearn; Caroline C Renner; Yan S Ding; Christina Vaughan-Watson; Stephen B Stanfill; Liqin Zhang; Gregory M Polzin; David L Ashley; Clifford H Watson
Journal:  Nicotine Tob Res       Date:  2013-01-03       Impact factor: 4.244

10.  Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography-mass spectrometry.

Authors:  Irina Stepanov; Peter W Villalta; Aleksandar Knezevich; Joni Jensen; Dorothy Hatsukami; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2010-01       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.